Octavio Espinoza - 17 Sep 2024 Form 4 Insider Report for LIGAND PHARMACEUTICALS INC (LGND)

Role
Chief Financial Officer
Signature
By: /s/ Andrew Reardon, Attorney-in-Fact For: Octavio Espinoza
Issuer symbol
LGND
Transactions as of
17 Sep 2024
Net transactions value
+$118,328
Form type
4
Filing time
19 Sep 2024, 17:50:09 UTC
Previous filing
30 Aug 2024
Next filing
24 Sep 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LGND Common Stock Options Exercise $114,380 +1,417 +5.8% $80.72 25,816 17 Sep 2024 Direct
transaction LGND Common Stock Options Exercise $3,948 +69 +0.27% $57.22 25,885 17 Sep 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LGND Employee Stock Option (right to buy) Options Exercise $0 -69 -0.94% $0.000000 7,240 17 Sep 2024 Common Stock 69 $57.22 Direct F1
transaction LGND Employee Stock Option (right to buy) Options Exercise $0 -1,417 -75% $0.000000 466 17 Sep 2024 Common Stock 1,417 $80.72 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 As per the separation of OmniAb Inc. from the issuer, 4,096 stock options were vested and exercisable as of November 1, 2022, whereas 3,766 options vest in 23 substantially equal monthly installments beginning on December 1, 2022.
F2 The stock option is fully vested and exercisable.